Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 124-148
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Study setting | Sample type | Marker type | Biomarker(s) and detection methods | Sensitivity (or its range) | Specificity (or its range) | Ref. |
Case-control | Stool | VOCs | Hydrogen sulphide, Dimethylsulphide, Dimethyldisulphide, mlz 90 - detected by selected ion flow tube (SIFT) mass spectrometry (MS) | 72.00% | 78.00% | [94] |
Case-control | Stool | VOCs | Propan-2-ol, 3-methylbutanoic acid - detected by gas chromatography (GC) and MS | 87.90% | 84.60% | [95] |
Case-control | Stool | VOCs | Methyl mercaptan (increased) and hydrogen (decreased) – detected by GC | 90.00% | 57.70% | [96] |
Case-control | Stool | VOCs | Pattern recognition technique - canine scent judgment | 97.00% | 99.00% | [97] |
Case-control | Stool | VOCs | Pattern recognition technique (eNose Cyranose® 320) | 85.00% | 87.00% | [94] |
Case-control | Stool | VOCs | Pattern recognition technique (SCENT A1) | 95.00% | 95.00% | [98] |
Case-control | Urine | VOCs | Ion mobility spectroscopy technology (FAIMS) | 88.00% | 60.00% | [99] |
Case-control | Urine | VOCs | Ion mobility spectroscopy technology (FAIMS) | 63.00% | 63.00% | [100] |
Case-control | Urine | VOCs | Pattern recognition technique (eNose applied) | 78.00% | 79.00% | [99] |
Case-control | Breath | VOCs | Pattern recognition technique - canine scent judgment | 91.00% | 99.00% | [97] |
Case-control | Breath | VOCs | Acetone (increased), ethyl acetate (increased), ethanol (decreased) and 4-methyl octane (decreased) detected by GC-MS | 85.00% | 94.00% | [99] |
Case-control | Breath | VOCs | Nonanal, decanal, 4-methyl-pentanone, 2-methylbutane, 4-methyloctane, 4-methylundecane, 2-methylpentane, methylcyclopentane, cycloxehane, methylcyclohexane, trimethyldecane-1,2-pentadiene, 1,3-dimethylbenzene, 1,4-dimethylbenzene – detected by GC-MS | 86.00% | 83.00% | [99] |
Case-control | Stool | Magnetic resonance spectra | Magnetic resonance spectra patterns | 85.20% | 86.90% | [101] |
Case-control | Stool | Small metabolites | Acetate – detected by proton magnetic resonance spectroscopy (PMRS) | 94.70% | 92.30% | [102] |
Case-control | Stool | Small metabolites | Succinate – detected by PMRS | 91.20% | 93.50% | [102] |
Case-control | Serum | Aromatic carboxylic acids | Benzoic acid – detected by CE-time of flight (TOF) MS | 89.00% | 82.00% | [103] |
Case-control | Serum | Fatty acids | GTA-446 – detected by flow injection analysis MS | 83.30% | 84.80% | [104] |
Case-control | Plasma | Amino acid metabolites | L-kynurenine – detected by high-performance liquid chromatography (HPLC) | 85.20% | 100.00% | [105] |
Case-control | Plasma | Fatty acids | Decanoic acid – detected by CE-TOFMS | 87.80% | 80.00% | [106] |
Case-control | Serum | Multiple metabolites | 38 metabolites detected by GC-MS | 85.00% | 86.00% | [107] |
Case-control | Serum | Phospholipids (sphingomyelins and phosphatidylcho-lines) | SM (34:1), PC (34:1), PC (34:2), PC (36:4), PC (36:2), PC (36:3) - detected by MS | ♂77.3%; ♀80.8% | ♂92.4%; ♀85.9% | [108] |
Case-control | Serum | Unsaturated free fatty acids (panel) | C16:1, C18:3, C20:4, C22:6, all downregulated – detected by MS | 93.80% | 92.20% | [109] |
Case-control | Serum | Amino acids (panel) | 8 amino acids – detected by LC-MS/MS | 65.00% | 95.00% | [110] |
Case-control | Serum | Amino acids, fatty acids, carbohydrates | 13 metabolites – detected by LC-MS/MS | 96.00% | 80.00% | [111] |
Case-control | Serum | Metabolite panel | 2-hydroxy-butyrate, aspartic acid, kynurenine, cystamine – detected by GC-MS | 83.10% | 81.00% | [112] |
Case-control | Serum | Lipid metabolites (panel) | Palmitic amide, oleamide, hexadecaneodioic acid, octadecanoic acid, eicosatrienoic acid, LPC(18:2), LPC(20:4), LPC(22:6), myristic acid, LPC(16:0) – detected by ion cyclotron resonance MS | 98.10% | 100.00% | [113] |
Case-control | Serum | Panel of hydroxylated polyunsaturated ultra long-chain fatty acids | C28H46O4, C28H48O4 and C28H50O4, all downregulated – detected by LC-MS/MS and nuclear MR | 75.00% | 90.00% | [114] |
Case-control | Serum | Multiple metabolites (panel) | 11,14-eicosadienoic acid, 12a-hydroxy-3-oxocholadienic acid, 12-ketodeoxycholic acid, 12-keto-tetrahydro-leukotriene B4, 13-cis-retinoic acid, 1b-hydrocholic acid, 1-methylhistamine, 1-monopalmitin, 2,3-dihydroxybutanoic acid, 24-hydroxycalcitriol – detected by GC-TOFMS and UPLC-QTOFMS | 83.70% | 91.70% | [115] |
Case-control | Plasma | Amino acids, fatty acids, carbohydrates | 8 metabolites – detected by CT-TQMS | 99.30% | 93.80% | [116] |
Case-control | Plasma | Choline-containing phospholipids (panel) | Total saturated lysophosphatidyl-cholines (LPCs), 18:2 LPC and sphingosylphosphorylcholine – detected by LC-MS/MS | 88.30% | 80.00% | [117] |
Case-control | Plasma | Choline-containing phospholipids (panel) | Total saturated lysophosphatidyl-cholines (LPCs) and the difference between 18:2 LPC and 18:1 LPC – detected by LC-MS | 82.00% | 93.00% | [118] |
Case-control | Dried blood | Amino acids and acylcarnitines (panel) | C16, Arg, C4/C8, C5/C3, Val, Phe/Tyr, Ala, C4/C3 – detected by direct infusion MS | 81.20% | 83.90% | [119] |
Case-control | Urine | Polyamines | N1, N12-diacetylspermine – detected by ELISA | 75.80% | 96.00% | [120] |
Case-control | Urine | Polyamines and amino acid metabolites | N1, N12-diacetylspermine and kynurenine – detected by LC-MS | 80.00% | 80.00% | [121] |
Case-control | Urine | Amino acids and acetoacetate (panel) | Alanine, glutamine, aspartic acid and acetoacetate – detected by PMRS | 87.50% | 91.30% | [122] |
Case-control | Urine | Nucleosides (panel) | 5-hydroxymethyluracil and 8-oxo-7,8-dihydroguanine – detected by UPLC-MS/MS | 78.60% | 75.00% | [123] |
Case-control | Urine | Nucleosides (panel) | Cytidine, 3-methylcitidine, 1-methyladenosine, 2-deoxyguanosine, adenosine, inosine – detected by HPLC-MS/MS | 69.00% | 98.00% | [124] |
Case-control | Urine | Metabolite panel | Citrate, Hippurate, p-cresol, 2-aminobutyrate, myristate, putrescine and kynurenate - detected by UPLC-QTOFMS | 97.50% | 100% | [125] |
Case-control | Urine | Nucleosides (panel) | Adenosine, N4-acetylcytidine, cytidine, guanosine, inosine, 1-methyladenosine, 1-methylguanosine, 1-methylinosine, 2-methylguanosine, 2,2-methylguanosine, N6-methyladenosine, uridine, 3-methyluridine+5-methyluridine, pseudouridine – detected by reverse phase HPLC | 76.90% | 90.40% | [126] |
Case-control | Urine | Nucleosides (panel) | Adenosine, N4-acetylcytidine, cytidine, guanosine, inosine, 1-methyladenosine, 1-methylguanosine, 1-methylinosine, 2-methylguanosine, 2,2-methylguanosine, N6-methyladenosine, 5-methyluridine, pseudouridine, uridine – detected by column switching HPLC | 71.00% | 96.00% | [127] |
- Citation: Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J Gastrointest Oncol 2020; 12(2): 124-148
- URL: https://www.wjgnet.com/1948-5204/full/v12/i2/124.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.124